Published October 15, 2013
Volume 21, Number 10

  • Global electronic leader Samsung Electro-Mechanics (SEMCO) has entered into a strategic partnership with Hacienda’s PowerbyProxi, allowing Samsung to use PowerbyProxi’s wireless power technology. The announcement signals SEMCO’s commitment to wireless power and wireless charging as a key technology for the future of consumer electronics and home appliances. PowerbyProxi also received $4 million in strategic funding from Samsung Ventures Investment Corporation. 

    “This is a major agreement for us in the consumer electronics market and enables us to leverage our wireless power technology and IP to deliver the best user experience to a mass audience,” says Fady Mishriki, PowerbyProxi EVP and CTO. “SEMCO’s extensive due diligence clearly demonstrates that the strength of our IP and engineering capabilities solve many of the technical challenges limiting current versions of wireless power. Our partnership is further evidence that wireless power and charging are fast becoming mainstream.”
  • Hacienda’s NeoTract, Inc., has received approval from the U.S. Food and Drug Administration (FDA) to market its UroLift System, the first permanent implant to relieve low or blocked urine flow in men age 50 and older with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.  The FDA’s action will provide U.S. surgeons and patients access to a treatment option that uniquely reduces urinary symptoms without chemically altering or surgically ablating, cutting, or removing prostatic tissue.  “FDA approval of the UroLift System marks a significant milestone for NeoTract and brings a truly minimally invasive treatment option to the millions of men suffering from BPH in the US,” says Dave Amerson, president and CEO of NeoTract, Inc.  “We have been very impressed with the thorough and efficient De Novo review process conducted by the FDA. We believe UroLift is a first line treatment option for patients with BPH given its strong therapeutic benefit and safety profile.”
  • In a recent publication, industry analysts IDC Health Insights evaluated all major CRM solution providers for life sciences and named Veeva Systems as a leader. The report states, “Veeva’s CRM software scored extremely well in this IDC MarketScape, with Veeva positioned in the Leaders category. Veeva CRM’s ease of use, user interface, and breadth of functionality are among the best in the industry, and the company’s sole focus on the life sciences industry boosts Veeva’s unique understanding of market wants and needs. This was echoed by the firm’s customers, who gave Veeva’s market expertise extremely high marks.”

Also in this issue ...